Obesity in Older People With and Without Conditions Associated With Weight Loss: Follow-up of 955,000 Primary Care Patients. by Bowman, Kirsty et al.
© The Author 2016. Published by Oxford University Press on behalf of The Gerontological Society of America.
203
Journals of Gerontology: Medical Sciences
cite as: J Gerontol A Biol Sci Med Sci, 2017, Vol. 72, No. 2, 203–209
doi:10.1093/gerona/glw147
Advance Access publication August 4, 2016
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, 
please contact journals.permissions@oup.com
E
d
ito
r’s C
h
o
ice
Research Article
Obesity in Older People With and Without Conditions 
Associated With Weight Loss: Follow-up of 955,000 
Primary Care Patients
Kirsty  Bowman,1 João  Delgado,1 William E.  Henley,2 Jane A.  Masoli,1 Katarina  Kos,3 
Carol Brayne,4 Praveen Thokala,5 Louise Lafortune,4 George A. Kuchel,6 Alessandro Ble,1 
and David  Melzer1,6; as part of the Ageing Well Programme of the NIHR School for 
Public Health Research, England
1Epidemiology and Public Health, Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, UK. 2Health 
Statistics Group, Institute of Health Research, University of Exeter Medical School, UK. 3Diabetes and Obesity Research Group, Institute 
of Biomedical and Clinical Science, University of Exeter Medical School, UK. 4Department of Public Health and Primary Care, Cambridge 
Institute of Public Health, University of Cambridge, UK. 5School of Health and Related Research (ScHARR), University of Sheffield, UK. 
6UConn Center on Aging, University of Connecticut Health Center, Farmington, USA.
Address correspondence to David Melzer, PhD, University of Exeter Medical School, RILD, Barrack Road, Exeter EX2 5DW, UK. E-mail: 
 D.Melzer@exeter.ac.uk
Received February 11, 2016; Accepted July 10, 2016
Decision Editor: Stephen Kritchevsky, PhD
Abstract
Background: Moderate obesity in later life may improve survival, prompting calls to revise obesity control policies. However, this obesity 
paradox may be due to confounding from smoking, diseases causing weight-loss, plus varying follow-up periods. We aimed to estimate body 
mass index (BMI) associations with mortality, incident type 2 diabetes, and coronary heart disease in older people with and without the above 
confounders.
Methods: Cohort analysis in Clinical Practice Research Datalink primary care, hospital and death certificate electronic medical records in 
England for ages 60 to more than 85 years. Models were adjusted for age, gender, alcohol use, smoking, calendar year, and socioeconomic status.
Results: Overall, BMI 30–34.9 (obesity class 1) was associated with lower overall death rates in all age groups. However, after excluding the 
specific confounders and follow-up less than 4 years, BMI mortality risk curves at age 65–69 were U-shaped, with raised risks at lower BMIs, 
a nadir between 23 and 26.9 and steeply rising risks above. In older age groups, mortality nadirs were at modestly higher BMIs (all <30) and 
risk slopes at higher BMIs were less marked, becoming nonsignificant at age 85 and older. Incidence of diabetes was raised for obesity-1 at all 
ages and for coronary heart disease to age 84.
Conclusions: Obesity is associated with shorter survival plus higher incidence of coronary heart disease and type 2 diabetes in older populations 
after accounting for the studied confounders, at least to age 84. These results cast doubt on calls to revise obesity control policies based on the 
claimed risk paradox at older ages.
Keywords: Paradox—Mortality—Overweight—BMI
From childhood to midlife, there is little question about the enor-
mous health burden associated with obesity. However, less severe 
obesity (body mass index “BMI” obese-1 = 30–34.9) in older people 
is reportedly associated with paradoxical outcomes in those aged 
≥65 years: for example, a 97 study meta-analysis found the obese-1 
group had similar mortality to normal weight (BMI 18.5–24.9) and 
that overweight (BMI 25–29.9) groups had lower mortality (1). 
Similarly, in 3.3 million older American veterans, the overweight 
(60 to <70 years; hazard ratio [HR] 3.63; 95% confidence interval 
[CI] 3.15–4.18) and obese-1 groups (HR 3.21; 95% CI 2.79–3.69) 
had a mortality advantage relative to the normal weight group (HR 
5.96; 95% CI 5.18–6.86, BMI 20 to <25) (2). Dixon and colleagues 
(3) have argued that this “obesity risk paradox” in older people is 
counter to “decades of advice to avoid even modest weight gain”, 
and that current weight control policies may be doing harm in older 
groups. There is therefore some urgency to clarify whether over-
weight or obese older people are or are not at greater risk of death 
and diseases related to adiposity.
BMI is the most widely used and practical clinical measure of 
adiposity in adults and children. In people aged 65 and older, BMI is 
correlated with body fat percentage measured by dual-energy x-ray 
absorptiometry (correlation 0.81 and 0.71 in women and men, 
respectively) (4). Conventional groupings of BMI were set by the U.S. 
National Heart, Lung, and Blood Institute (5) and the World Health 
Organization (6). However, these cut-points are disputed especially 
for those of South Asian origin (7), and older groups (8–11).
Various explanations have been offered for the obesity paradox 
in older people, including potential biological mechanisms (12). 
Smoking is associated with lower weight and markedly raised health 
risks and can therefore distort regression estimates, even when used 
to adjust models (13). At older ages, several diseases cause both 
weight loss and increased mortality, introducing reverse causation 
confounding into models (14).
To clarify obesity risks in later life, large sample sizes are needed 
to provide separate estimates for different subgroups of older peo-
ple. We analyzed Clinical Practice Research Datalink (CPRD) data 
of near-complete older populations in England registered with pri-
mary care. We estimated associations in age group–specific cohorts 
between baseline BMI and incident type 2 diabetes, coronary heart 
disease (CHD), and all-cause mortality during follow-up in older 
people with and without the potential confounding effects of smok-
ing and diseases associated with weight loss.
Methods
Study Design
Deidentified electronic medical record data were from CPRD (15), 
and included  General Practitioner (GP) records linked to Hospital 
Episode Statistics (HES) data for admissions (available for England 
only) and Office for National Statistics death certificate data. 
Registration with GPs is nearly complete and includes patients in 
institutional settings. The CPRD database includes essentially all 
patients who are registered with CPRD participating general prac-
tices with very few patients withdrawing their data during the study 
period. CPRD diagnostic and outcome coding has generally high 
validity (16), improved further with hospital and death certificate 
data. CPRD has Multiple Research Ethics Committee approval (05/
MRE04/87) to undertake purely observational studies, with exter-
nal data linkages including HES and Office for National Statistics 
mortality data. The work of CPRD is also covered by NIGB-ECC 
approval ECC 5-05 (a) 2012. This study was approved by the 
Independent Scientific Advisory Committee for MHRA database 
research under protocol number 14_135 (2014).
All patients with BMI (usually measured) records since January 
1, 2000 and registered with a CPRD practice were included 
(n  =  955,031; 62% of patients), with GP record inclusion to 
November 17, 2014. Those with BMI measures had better survival 
(age, sex, and deprivation-adjusted Cox regression HR = 0.46; 95% 
CI 0.45–0.46) and were more likely to have chronic kidney disease, 
diabetes, or hypertension, but less likely to have heart failure or 
dementia (Supplementary Table S1).
We excluded outlier values of BMI (<14.0 and >56.5) (n = 6,431). 
We used the earliest recorded BMI within each age group 60–64, 
65–69, 70–74, 75–84, and ≥85 years (termed “index” BMI for analy-
sis), but did not include patient duplications within age-specific mod-
els. For instance, a person could be included in the 60–64 age-group 
model and the 70–74 age-group model if they met all the inclusion 
criteria. Excluding people from subsequent age-group models could 
result in a disproportionate number of patients who joined practices 
later or avoided contact with practices in the older age groups. BMI 
was grouped by World Health Organization cut-points but we com-
bined obese class 2 and 3 in the 85 and older group as there were 
less than 200 patients.
In patients with more than one BMI measure, weight stability 
was derived (data available for 53.1% patients aged 60–64; 58.0% 
aged 65–69; 61.0% aged 70–74; 57.4% aged 75–84; and 62.7% 
≥85 years). Patients were classified as substantial weight losers (lost 
≥5 kg), weight gainers (gained ≥5 kg), or weight stable (loss or gain 
<5 kg), using the weight difference between the study index weight 
and the mean of all weight records recorded over the preceding 
4  years. Smaller fluctuations in weight could reflect measurement 
errors, acute events, or minor changes due to dieting. The con-
founder effect of substantial weight loss was estimated in sensitiv-
ity analyses for patients with repeat BMI measures. The sample was 
predominantly “white” ethnicity, for example, in 65–69-year olds, 
81.8% had ethnicity data of whom 95.0% were “white” and 2.3% 
were South Asian.
Empirical models for exclusions
To identify groups most susceptible to prior weight loss, we tested 
associations with 15 major diagnoses ascertained before BMI 
measures (see Supplementary Table S1 for details). We also identi-
fied patients having greater than 6 of 36 Rockwood frailty index 
conditions (17), using ResearchOne Electronic Frailty Index coding 
rules. In age- and gender-adjusted regression models, recent cancer 
(within 5  years, excluding nonmelanoma skin cancer), dementia, 
heart failure, and multimorbidity all yielded statistically significant 
odds ratios ≥1.5 for weight loss, with other conditions having ORs 
less than 1.4. We therefore excluded the named conditions from 
models, to identify a “healthier ager” subgroup. We plotted hazards 
for mortality for 2-year follow-up periods to guide how many years 
to exclude to limit reverse causality. There is no agreement on how 
many years of follow-up period should be excluded, for instance, 
some studies have used all the follow-up period (12), whereas, others 
have excluded up to 5 years (18).
Covariates
Smoking status was based on GP-recorded Read terms in the previous 
10 years. Patients were classified as current (or recent) smokers, ex-
smokers, never smokers, and not recorded. Alcohol status was based 
on GP-recorded Read terms and units of alcohol per week (where 
available) in the previous 10 years (heavy drinkers were defined as 
>35 units for women and >50 units for men). Patients were classified 
as heavy drinkers, nondrinkers, current drinkers, former drinkers, and 
not recorded. Relative socioeconomical status was measured by the 
Index of Multiple Deprivation 2007 (19), calculated on each patient’s 
residential postal code and incorporating seven deprivation domains 
(income, employment, education, health, crime, barriers to housing 
and services, and living environment) and categorized by quintiles (1 
least deprived). Calendar year was included as a covariate to account 
for changing trends in BMI recording and medical care during base-
line selection. Physical activity was recorded in CPRD as inactive, 
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gentle activity, moderate activity, vigorous activity, or not recorded 
(most recent data preceding index BMI but up to 10 years before).
Outcomes
Outcomes were incident angina or myocardial infarction diagnoses 
from ICD10-coded hospital inpatient records, incident type 2 dia-
betes (from GP or hospital records), and mortality (from Office for 
National Statistics death certificate data).
Statistical Analysis
For BMI category mortality analyses, we used Cox Proportional haz-
ards models with follow-up years as the timescale. We used spline mod-
els with four knots to estimate nonlinear associations between BMI as 
a continuous measure and mortality, using the exclusions previously 
detailed. For subsequent analyses, we had preplanned to revise the BMI 
groupings based on the spline point curves. We used competing risks 
models (accounting for mortality) for the CHD and diabetes events. 
The proportional hazards assumption was tested for each model using 
Schoenfeld residuals. Missing values for smoking and alcohol intake 
were multiply imputed using the chained (mlogit) multinomial logistic 
regression approach. We used the rate advancement periods approach 
to estimate the effective age of BMI exposure group (20), essentially the 
number of additional years of aging in the control group that would 
result in equivalent mortality risks to those experienced by the exposed 
group. Analyses were carried out using Stata statistical software (ver-
sion 13.1) and R statistical software (version 3.1.2.) with packages 
“pspline” (version 2.37–7) and “survival” (version 1.0–16).
Results
There were 955,031 patients in analyses (n = 822,811 with complete 
data for covariates), with 1,540,553 patient follow-ups from some 
contributing in more than one age-specific analysis. The maximum 
follow-up was 14.9 years (mean 5.97 years, SD = 4.02).
Mean BMI was 28.2 kg/m2 in the 60–64-year group and 24.8 kg/
m2 in the 85 and older group (Table 1, Table 2 and Supplementary 
Table S2). Covariate distributions also showed age-group trends 
with, for example, current or recent smoking declining from 34.2% 
in the 60–64 group to 19.7% in the 85 and older group. Substantial 
measured weight loss was present in 5.2% and 11.5% of the young-
est and oldest groups, respectively.
Overall, 13.2% (n = 48,442) of the 65–69-year olds died during 
follow-up, with rates rising to 56.9% (n = 67,814) in the 85 and 
older age group (Supplementary Table S3). Group mean BMI decline 
was modestly lower with advancing age, and it was also progres-
sively lower over the 13 years before death, especially in the final 
few years (Figure 1): for example, in those aged 65–69 at baseline, 
34% were obese-1 13 years before death but only 24% in the year 
of death, while the “normal” weights increased from 23% to 39% 
over the same period.
Using models similar to those producing paradoxical associa-
tions, we computed Cox proportional hazards for all-cause mortality 
for all subjects with complete data, adjusting for age, gender, alcohol 
intake, smoking status, calendar year, and a measure of relative soci-
oeconomic position. We included all follow-up data from baseline to 
14.9 years (Supplementary Table S4). In the 65–69-year age group 
(n = 312,352 with 40,815 deaths), the obese-1 group had a lower 
mortality hazard than the normal BMI group (obese-1 HR = 0.91; 
95% CI 0.88–0.93), and estimates were even more paradoxical 
for the overweight group (HR  =  0.79; 95% CI 0.77–0.81). The 
mortality hazards were raised (nonparadoxical) in the obese-2 group 
(HR = 1.07; 95% CI 1.02–1.11) and obese-3 groups (HR = 1.54; 
95% CI 1.46–1.63). Paradoxical hazards were present across the 
other age groups studied. Incidentally, the highest HRs were for the 
underweight category (HR = 2.54; 95% CI 2.40–2.69 at age 65–69).
We then excluded current smokers plus patients with multimor-
bidity, heart failure, dementia, or recent cancer at baseline (ie, condi-
tions most strongly associated with prior weight loss: see Methods 
and Supplementary Table S1) to provide estimates for the remaining 
group, termed “healthier agers.” We plotted hazards for 2-year fol-
low-up periods to examine the stability of estimates (Supplementary 
Figure S1 and Supplementary Table S5). In the 65–74 age group, the 
obese-1 group had a survival advantage during the first 2  years of 
follow-up only, but this reversed rapidly thereafter. Hazards for the 
other BMI categories showed similar patterns, all reaching stability 
after 4 years (except for the underweight group which stabilized after 
6 years). In subsequent healthier ager modeling, we therefore excluded 
the 0–3.9 years follow-up data, to estimate stable longer-term hazards.
Healthier ager only models showed raised (nonparadoxical) mor-
tality hazards for the obese-1 group to age 74 (Supplementary Table 
S4): in the 65–69 age-group HR = 1.17 (95% CI 1.11–1.23) compared 
to the normal BMI category. In the overweight group at age 65–69, 
the apparent protective effect also reversed to yield a nonsignificant 
difference from the conventional normal group (HR = 0.96; 95% CI 
0.92–1.01). For continuous BMI, using the spline point regression 
(Figure 2 and Supplementary Figure S2), in the lower end of normal 
BMI range (18.5–22.9) hazards rise very sharply with reducing BMI. 
The lowest relative hazards were approximately between BMI 23 and 
26.9 at ages 60–69, although a little higher in older groups. Hazards 
increased moderately from BMI 27–29.9 and steeply at higher BMIs 
in the obese range. We therefore estimated healthier ager model haz-
ards with a comparison group of BMI 23–26.9, the lowest part of 
the risk curve, which produced slightly larger effect sizes than with 
the conventional BMI categories (Supplementary Table S6). Applying 
the rate advancement period approach, the healthier ager obese-1 
group have mortality rates equivalent to being 1.96 years older than 
their chronological age (compared to lowest mortality BMI 23–26.9), 
with bigger age accelerations in the obese-2 (3.51 years) and obese-3 
groups (7.38 years) (Supplementary Table S7). Age acceleration in the 
BMI 27 to 29.9 group was 0.52 of a year.
Type 2 Diabetes and CHD Events
Healthier ager models showed competing hazards for diabetes in 
both the obese-1 and BMI 27–29.9 overweight group were raised 
in all age groups (Table 3). The hazards for the 65–69 age group for 
the overweight and obese-1 group were HR 1.79 (1.67–1.93) and 
2.68 (2.49–2.88), respectively. For CHD, competing hazards were 
raised in BMI 27–29.9 overweight groups in all age groups, with the 
obese-1 group having raised hazards to age 84 and a nonsignificant 
estimate in the 85 and older group (Table 3). The hazards for the 
65–69 age group for the overweight and obese-1 group were HR 
1.14 (1.07–1.22) and HR 1.26 (1.17–1.35), respectively.
Sensitivity Analyses
We carried out a series of sensitivity analyses for gender differences 
(among the several analyses, only the 70–74 age group had a sig-
nificant interaction and the CIs overlapped for men and women 
within each BMI category), adjustment for physical activity meas-
ures (Supplementary Table S8), restricting estimates to the “white” 
group (Supplementary Table S9), with measured weight change only 
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(Supplementary Table S10), excluding measured weight losses of 
≥2.5 kg (rather than >5 kg) (Supplementary Table S10), and multiple 
imputation for smoking and alcohol intake (Supplementary Table 
S11). Results were little changed. Estimated hazard for mortality for 
smokers plus patients with multimorbidity, heart failure, dementia, 
or recent cancer (Supplementary Table S4) were markedly paradoxi-
cal for overweight and obese-1 groups. Paradoxical associations for 
the obese-1 (age group 65–69 HR 0.77; 95% CI 0.74–0.81) and 
obese-2 groups (age group 65–69 HR 0.86; 95% CI 0.81–0.92) for 
mortality were found in current smokers only models. There were 
lower risks for mortality for the obese-1 (age group 65–69 HR 0.68; 
95% CI 0.64–0.71) and obese-2 groups (age group 65–69 HR 0.75; 
95% CI 0.70–0.81) in models that included only patients with con-
ditions associated with weight loss.
Discussion
Several analyses have reported that older overweight and moder-
ately obese subjects have better or similar survival to normal BMI 
groups, apparently undermining the scientific rationale for some 
responses to the global obesity epidemic. In models ignoring sug-
gested confounding, we obtained similar paradoxical estimates. 
However, in models focused on healthier agers (ie, nonsmoking and 
free of disease-associated weight loss) obesity class-1 was associated 
with increased hazards for all-cause mortality, CHD, and diabetes 
compared to risk nadir, at least to age 85 and older. For healthier 
agers, therefore, our results do not support calls to revise policies to 
reflect the claimed obesity risk paradox in the general older popula-
tion. At age 65, healthy agers have long life expectancies (women 
21.0 years, men 18.5, for England (21)) during which gains from 
optimized weight control could be enjoyed. Our evidence on being 
overweight at older ages is mixed, but BMI >27 was associated with 
modestly increased mortality at the younger studied ages compared 
to the lowest risk BMI range of 23–26.9.
Analyzing clinical records offers advantages (eg, large samples, 
near-complete population inclusion, clinically recorded diagnoses 
plus no loss to follow-up in outcome ascertainment) but recording 
of risk factors can be incomplete or triggered by clinical events. This 
problem is somewhat reduced here as GPs were offered financial 
incentives to record cardiovascular risk measures in the time period 
included in our analyses.
There are no data on whether weight loss was intentional or not, 
but a 1996 study in British primary care found that 18% of 56 to 
75-year olds experienced any perceived weight loss in the previous 
4  years, with only 4% citing personal reasons unrelated to health 
concerns or physician advice (22). Our exclusion of diseases empiri-
cally most strongly associated with measured weight loss is systematic 
but incomplete: in the weight change subgroup (age 65–69), 25.1% 
of the patients with greater than 5 kg weight loss would remain in 
the analysis despite the healthier ager model disease exclusions. This 
residual confounding may explain the paradoxical estimates in the 
Figure  2. Spline point estimates for continuous body mass index by age 
group for the “healthier agers.”
Table 2. BMI Category Distribution by Age Group
Age Group (y)
60–64 65–69 70–75 75–84 85 and Older
BMI (kg/m2), n (%)
 Underweight: 14.0 to <18.5 3,882 (1.1) 3,917 (1.3) 4,443 (1.7) 7,692 (2.8) 6,260 (6.5)
 Normal weight: 18.5 to <25.0 93,428 (27.4) 86,315 (27.6) 78,498 (29.5) 100,107 (36.0) 46,396 (48.1)
 Overweight: 25.0 to <30.0 135,154 (39.7) 126,911 (40·6) 109,126 (41.0) 109,431 (39.3) 31,720 (32.9)
 Obese-1: 30.0 to <35.0 72,102 (21.2) 64,981 (20.8) 52,292 (19.7) 45,264 (16.3) 9,823 (10.2)
 Obese-2: 35.0 to <40.0 24,888 (7.3) 21,247 (6.8) 15,827 (6.0) 12,201 (4.4) 1,891 (2.0)
 Obese-3: ≥40.0 11,299 (3.3) 8,981 (2.9) 5,726 (2.2) 3,727 (1.3) 408 (0.4)
BMI = body mass index.
Figure  1. Cross-sectional estimates of the percentage of subjects by 
conventional body mass index category and number of years to death, for 
the 65–69 age group. 
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oldest old and in the first years of follow-up, and may have resulted in 
some underestimation of the risks of being overweight.
Our results are difficult to compare with previous work, as most 
reports were based on smaller samples of older volunteers, with vary-
ing groupings of BMI and varying follow-ups. Also, most reports 
relate to patients who were less exposed to modern cardiovascular 
and diabetes interventions. Lu and colleagues (2) recently reported an 
analysis of 3.3 million patients admitted to Veterans Administration 
hospitals, and those aged 60–69 years old in obese class 1 had mark-
edly lower mortality compared to normal BMI, but no subgroup anal-
ysis excluding smokers and prior weight loss was reported. A recent 
meta-analysis in older people reported increasing mortality hazards 
at BMIs greater than 33 kg/m2 for a pooled 65 and older age group, a 
substantially higher threshold for increased hazards than in our esti-
mates (11). Berrington and colleagues pooled 19 studies and excluded 
smokers and those with cancer, heart disease or aged ≥85 years, yield-
ing relatively small numbers of deaths to analyze (2,754 and 546 
deaths in obese-1 aged 60–69 and 70–84, respectively), but reported 
similarly raised hazards for mortality in their obese-1 older group (23). 
Our result are also broadly similar to an earlier meta-analysis of 57 
studies (median recruitment year 1979, mean baseline age 46 years, 
2% of the subjects aged ≥70 at baseline) although this reported that 
the lowest mortality risk, after excluding the first 5 years of follow-up, 
was within the BMI range 22.5–25 kg/m2 (18).
We have shown that there are substantially raised absolute 
death rates in later life in obese groups at least to age 84, and also 
raised risks of diabetes and CHD. In addition, obesity is associated 
with substantial excess disability and mobility limitations (24,25). 
Stenholm and colleagues reported that obese (BMI ≥ 30 kg/m2) men 
and women aged 70–79  years from the Health, Aging and Body 
Composition Study had an increased risk of mobility limitation dur-
ing a 6.5-year follow-up period (26). Obese men and women aged 
65 years and older from the English Longitudinal Study of Ageing 
were reported to have an increased risk of self-reported difficul-
ties with activities of daily living and with a measure of functional 
impairment during a 5-year follow-up period (27). Basing calls for 
revising current obesity control policies on the claimed obesity risk 
paradox in the general older population is therefore inappropriate. 
Clinical advocacy of weight control for general health risk reduction 
was never claimed to be relevant to those already suffering from 
conditions associated with weight loss.
Further work is needed to clarify whether the apparently protec-
tive effects of being obese in smokers and those with diseases causing 
weight loss represents real protective effects (sometimes referred to 
as the obesity paradox in chronic disease) or whether BMI in such 
groups is a measure of disease severity. Further research is required 
into dynamic changes in BMI with mortality, especially in the oldest 
age groups. Further work is also needed on whether more specific 
measures of adipose tissue mass in older people add significantly 
to risk estimation for targeting of interventions. Revision of nor-
mal ranges for BMI in later life would be useful, as the classification 
includes groups at BMIs below 23, which are associated with sub-
stantially increased mortality in older groups.
Conclusions
In this large population-based older cohort studying longer-term 
outcomes, our results show that obesity is associated with shorter 
survival in older people who do not have the studied confounding 
factors, at least to age 84. These results cast doubt on calls to revise 
obesity control policies to reflect the claimed obesity risk paradox 
in the general older population. The conventional normal BMI cat-
egory appears too broad for older people as it includes BMIs below 
23, which are associated with higher mortality.
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Table 3. Competing Sub-Hazard Ratios for Incident Coronary Heart Disease and Type 2 Diabetes for “Healthier Agers”
Age Group (y)
60–64* 65–69* 70–74* 75–84* 85 and Older*,†
Coronary heart disease
 Underweight: 14.0 to <18.5 0.65 (0.38–1.09) 0.96 (0.68–1.37) 0.85 (0.64–1.12) 0.79 (0.65–0.95) 0.60 (0.43–0.85)
 Low-normal‡,§: 18.5 to <23.0 0.79 (0.70–0.89) 0.84 (0.76–0.93) 0.91 (0.83–0.99) 0.89 (0.83–0.95) 0.97 (0.85–1.11)
 Reference: 23.0 to <27.0 1 1 1 1 1
 Overweight‡,§: 27.0 to <30.0 1.16 (1.07–1.26) 1.14 (1.07–1.22) 1.12 (1.05–1.19) 1.10 (1.03–1.16) 1.22 (1.05–1.42)
 Obese-1: 30.0 to <35.0 1.25 (1.15–1.36) 1.26 (1.17–1.35) 1.19 (1.11–1.28) 1.11 (1.04–1.19) 1.03 (0.84–1.26)
 Obese-2: 35.0 to <40.0 1.44 (1.28–1.62) 1.30 (1.16–1.45) 1.17 (1.04–1.32) 1.10 (0.97–1.25) 1.12 (0.74–1.67)
 Obese-3: ≥40.0 1.49 (1.26–1.77) 1.21 (1.02–1.45) 0.97 (0.77–1.21) 1.22 (0.97–1.55) _
Type 2 diabetes
 Underweight: 14.0 to <18.5 0.19 (0.07–0.51) 0.27 (0.13–0.56) 0.32 (0.18–0.55) 0.45 (0.32–0.64) 0.68 (0.39–1.18)
 Low-normal‡,§: 18.5 to <23.0 0.50 (0.44–0.59) 0.56 (0.49–0.64) 0.61 (0.54–0.69) 0.65 (0.58–0.72) 0.77 (0.60–0.98)
 Reference: 23.0 to <27.0 1 1 1 1 1
 Overweight‡,§: 27.0 to <30.0 1.83 (1.70–1.98) 1.79 (1.67–1.93) 1.55 (1.43–1.67) 1.48 (1.36–1.60) 1.53 (1.20–1.97)
 Obese-1: 30.0 to <35.0 3.05 (2.83–3.28) 2.68 (2.49–2.88) 2.16 (2.00–2.34) 1.98 (1.81–2.16) 1.41 (1.02–1.95)
 Obese-2: 35.0 to <40.0 4.43 (4.04–4.87) 3.66 (3.32–4.05) 3.18 (2.84–3.56) 2.55 (2.20–2.94) 3.88 (2.47–6.08)
 Obese-3: ≥40.0 5.59 (4.92–6.34) 4.68 (4.07–5.38) 3.18 (2.61–3.87) 2.19 (1.62–2.95) _
*Cell contents: events/number, Sub-Hazard Ratios (SHR) (95% CI).
†In the 85+ group, obese-2 and obese-3 are combined.
‡Revised low-normal§ = BMI: 18.5 to <23.0, reference = 23.0 to <27.0, revised-overweight§ = 27.0 to <30.0.
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